Pharmaceuticals & Biotech French Community

Abivax’s lead drug shows strong late-stage results for ulcerative colitis, and the company now has enough cash runway to focus on getting it approved and launched. A simple-to-take treatment and possible interest from a bigger drug company could change how investors see it.Read more

Eurofins faces a tougher future as automation, clients bringing testing in-house, and rising data and safety rules squeeze the economics of traditional lab work. The upside case hinges on whether its big tech and lab upgrades, plus careful deal-making, can lift efficiency fast enough to offset tougher pricing power.Read more

DBV Technologies is betting that a skin patch for peanut allergy can become a go-to option for children, and it’s gearing up to move from years of testing into a real product launch. The big upside hinges on smooth regulator sign-off and convincing long-term results across younger age groups, while delays, safety questions, and tough competition could hold the business back.Read more

Euroapi looks like it could benefit as drugmakers push to make more ingredients closer to home and choose cleaner manufacturing methods, with new technology and government support helping it rebuild profitability. But it still leans heavily on a few big customers and faces tough pricing pressure, which could limit how much of that upside actually shows up in results.Read more

Ipsen looks set to ride a wave of growing demand for specialty medicines, with new cancer and rare-disease treatments that could spread faster than many expect and boost profits along the way. The big catch is that the business leans heavily on a handful of key drugs, so competition from copycat versions, tougher pricing, or slower approvals could quickly change the story.Read more

Nanobiotix is trying to ride the growing use of radiation therapy in cancer care, while also building a second platform that could help other drugmakers deliver hard-to-target medicines. The big question is whether its major clinical trials and partnership talks deliver real proof and deals—or leave the company spending heavily without a clear payoff.Read more

Sanofi’s growth leans heavily on one blockbuster medicine, and its push to expand the pipeline and vaccines business could bring bigger spending and more chances for setbacks. See why this mix of dependence, deal-making, and ambitious research plans could make future profits less predictable than many expect.Read more

MedinCell’s long-acting shots could ride a real shift toward treatments that last longer, but near-term bumps may come from regulators, insurers, and partner timelines. If its flagship partnered medicine keeps gaining traction and new programs move forward, the payoff could be meaningful—yet delays and rising research spend may test patience.Read more

Euroapi is trying to rebuild its drug-ingredient business by expanding production, investing in new biotech-style manufacturing, and shifting toward higher-value work for big pharmaceutical customers. The upside is a steadier, more profitable mix, but intense low-cost competition, heavy reliance on a few customers, and the strain of a major restructuring could derail the turnaround.Read more